Targeted therapies in neuroendocrine neoplasms
Journal Title: OncoReview - Year 2012, Vol 2, Issue 3
Abstract
The primary treatment of gastrointestinal neuroendocrine tumors is surgery, and its extent depends on the clinical stage of cancer. In advanced disease medical therapy is used. One possible form of treatment is biological therapy and radionuclide therapy (PRRT, peptide receptor radionuclide therapy) using radiolabeled somatostatin analogues. The effects of these treatments can improve the combinations of radioactive labeled somatostatin analogues, intra-arterial administered, and the use of radio sensitizing drugs combined with PRRT or PRRT combined with new targeted therapeutic agents such as sunitinib or everolimus. New targeted agents (angiogenesis inhibitors, single and multiple tyrosine kinase inhibitors and new somatostatin analogues, such as pasyreotyd) also evaluated in II and III phase clinical trials. Currently, there are several studies on the efficacy of a combination of different, present and new treatments. PRRT with the combination of sunitinib or everolimus or sequential use of PRRT and one of these compounds may be a promising solution for the treatment of patients with pancreatic endocrine tumors.
Authors and Affiliations
Violetta Rosiek, Beata Kos-Kudła
Nefrotoksyczność leków stosowanych w chemioterapii nowotworów
Rozwój onkologii klinicznej oraz coraz częstsza zapadalność na nowotwory powodują szybkie zwiększanie się grupy chorych leczonych chemioterapeutykami. Stosowanie tych leków oprócz korzyści niesie ze sobą również ryzyko w...
Acquired haemophilia in a patient with neoplastic disease
Acquired haemophilia A (AH) is a rare autoimmune disorder caused by inhibitory antibodies against coagulation factor VIII and characterized by spontaneous hemorrhage in patients with no previous personal or family histor...
Follicular mucinosis on the forehead of a 15-year-old girl
Follicular mucinosis is a rare dermatosis characterized by accumulation of mucin in the follicular epithelium and sebaceous glands. Clinically, it is characterized by the presence of papules or well-circumscribed and inf...
Rola lapatynibu w leczeniu HER2-dodatniego raka piersi
Rak piersi z nadekspresją receptora HER2 lub amplifikacją jego genu stanowi ok. 25–30% zachorowań i wiąże się z bardziej agresywnym przebiegiem i gorszym rokowaniem. Wprowadzenie trastuzumabu – pierwszego leku celowanego...
Cardiac Biomarkers and Early Detection of Cardiotoxicity